Active, not recruitingPhase 2NCT05715216

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Shannon Westin, MD, MD
M.D. Anderson Cancer Center
Intervention
Nivolumab(drug)
Enrollment
20 target
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

Mereo BioPharma

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05715216 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials